Cavitation Technologies, Inc.
Cavitation Technologies, Inc. develops and commercializes systems for processing industrial liquids, using its patented Nano Reactor and Low Pressure Nano Reactor technologies. Its applications include water and wastewater treatment, agricultural water remediation, and alcoholic beverage processing. The company’s products include the Nano Neutralization System for vegetable oil refining, which it licenses for use in that field, and systems for treating produced and frac water. It also develops Hydro-Plasma water treatment technology and licenses cavitation technology to its wholly owned subsidiary, Xyra Corp., for computing infrastructure and digital payment applications. Cavitation Technologies makes money through reactor and system sales, technology licensing royalties, and related leasing, consulting and manufacturing fees. It has licensing arrangements for alcoholic beverage technology with Alchemy Beverages and a 50% interest in Enviro WaterTek, which is pursuing water treatment applications. The company is headquartered in Chatsworth, California.
No SEC Form 4 filings for $CVAT in the last 30 days.
See all $CVAT insider activity →Cavitation Technologies (CVAT) received a tender offer from BrightFlixx for all outstanding shares. The board considers the offer fair and premium to recent prices but awaits final price and fairness opinion for a recommendation.
Cavitation Technologies reported 2026 Q2 revenue of $0, down from $3K YoY, with net loss narrowing to $208K. Prior-year revenue was from a Nano Reactor rental. A 2024 patent transfer to Desmet may reduce future sales. The company's water-treatment system is being tested, with sales of Barmuze and Hydro-Plasma expected in 2027.
Cavitation Technologies (CVAT) and Alchemy Beverages (ABI) agreed to tender offers for BrightFlixx, totaling $42 million. CVAT's offer is $35 million, ABI's is $7 million, both subject to conditions. They terminated earlier agreements with European Guarantee Services. Pricing and closing details will be finalized after a 45-business-day record date.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning CVAT (Cavitation Technologies, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent CVAT coverage spans corporate actions, mergers & acquisitions and earnings.
Tender offer creates potential premium to current price.
Micro‑cap earnings release with negligible revenue and modest loss.
The tender offer creates a potential premium to current market price, likely driving buying pressure.
The tender offer creates potential upside for shareholders if the transaction proceeds.
Definitive tender-offer financing terms are a near-term catalyst that can tighten spreads and increase buyback/tender arbitrage interest, but execution depends on filings and conditions.
AlphAI scores every news story that mentions CVAT with an AI model for sentiment and relevance, and aggregates insider trades from Cavitation Technologies, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Cavitation Technologies (CVAT) received a tender offer from BrightFlixx for all outstanding shares. The board considers the offer fair and premium to recent prices but awaits final price and fairness opinion for a recommendation.
Cavitation Technologies reported 2026 Q2 revenue of $0, down from $3K YoY, with net loss narrowing to $208K. Prior-year revenue was from a Nano Reactor rental. A 2024 patent transfer to Desmet may reduce future sales. The company's water-treatment system is being tested, with sales of Barmuze and Hydro-Plasma expected in 2027.
Cavitation Technologies (CVAT) and Alchemy Beverages (ABI) agreed to tender offers for BrightFlixx, totaling $42 million. CVAT's offer is $35 million, ABI's is $7 million, both subject to conditions. They terminated earlier agreements with European Guarantee Services. Pricing and closing details will be finalized after a 45-business-day record date.
Cavitation Technologies, Inc. (CVAT) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Cavitation Technologies, Inc. Announces Definitive Agreements with BrightFlixx Finance (Luxembourg) S.A. for Aggregate Proposed Cash Consideration of $42 Million CHATSWORTH, Calif., October 9, 2026 (GLOBE NEWSWIRE) -- Cavitation Technologies, Inc. (OTCQB: CVAT) ("CVA
Cavitation Technologies (CVAT) signed agreements with BrightFlixx Finance for $42M cash tender offers, including $35M for CVAT and $7M for Alchemy. The offers replace prior agreements and are pending regulatory filings and conditions.
Cavitation Technologies reported FY 2026 revenue of $3K, down 98.5% YoY, and a net loss of $1.4M, widened from $113K. The decline was due to a shift from product sales to rental and demo income. The company assigned vegetable oil refining patents to Desmet, retaining exclusive licenses for other markets. Cash constraints led to reduced R&D and reliance on partners for commercialization.
Cavitation Technologies, Inc. (CVAT) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Cavitation Technologies, Inc. Executes Definitive Purchase Agreement with European Guarantee Services S.à.r.l CHATSWORTH, CA – August 17, 2026 (GLOBE NEWSWIRE) – Cavitation Technologies, Inc. (OTCQB: CVAT) ("CVAT" or the "Company"), a leading provider of sustainable
